Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells

Journal of Medicinal Chemistry

Volumn 54, Issue 21, 2011, Pages 7523-7534

  Soudy, Rania ^a   Gill, Avneet ^a   Sprules, Tara ^b   Lavasanifar, Afsaneh ^a   Kaur, Kamaljit ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE DERIVATIVE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DRUG CYTOTOXICITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN DEGRADATION; PROTEIN SECONDARY STRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CIRCULAR DICHROISM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIVER; MICE; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEOLYSIS; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80455162612     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200750x     Document Type: Article

References (53)

1. Takimoto, C. H.; Calvo, E. Principles of Oncologic Pharmacotherapy In Cancer Management: A Multidisciplinary Approach, 11 th ed.; Pazdur, R., Wagman, L. D., Camphausen, K. A., Hoskins, W. J., Eds.; CMP: Manhasset, NY, 2008.
2. Abrous-Anane, S.; Savignoni, A.; Daveau, C.; Pierga, J.-Y.; Gautier, C.; Reyal, F.; Dendale, R.; Campana, F.; Kirova, Y. M.; Fourquet, A.; Bollet, M. A. Management of Inflammatory Breast Cancer after Neoadjuvant Chemotherapy Int. J. Radiat. Oncol., Biol., Phys. 2011, 79, 1055-1063
3. Raschi, E.; Vasina, V.; Ursino, M. G.; Boriani, G.; Martoni, A.; De Ponti, F. Anticancer Drugs and Cardiotoxicity: Insights and Perspectives in the Era of Targeted Therapy Pharmacol. Ther. 2010, 125, 196-218
4. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J.-P.; Koch, M.; Monneret, C. Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy Cancer Res. 1998, 58, 1195-1201
5. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Wong, W. L.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W. Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index Nat. Biotechnol. 2008, 26, 925-932
6. Govindan, S. V.; Goldenberg, D. M. New Antibody Conjugates in Cancer Therapy TheScientificWorldJournal 2010, 10, 2070-2089
7. Aina, O. H.; Sroka, T. C.; Chen, M.-L.; Lam, K. S. Therapeutic Cancer Targeting Peptides Pept. Sci. 2002, 66, 184-199
8. Laakkonen, P.; Zhang, L.; Ruoslahti, E. Peptide Targeting of Tumor Lymph Vessels Ann. N.Y. Acad. Sci. 2008, 1131, 37-43
9. Lyakhov, I.; Zielinski, R.; Kuban, M.; Kramer-Marek, G.; Fisher, R.; Chertov, O.; Bindu, L.; Capala, J. HER2- and EGFR-Specific Affiprobes: Novel Recombinant Optical Probes for Cell Imaging ChemBioChem 2010, 11, 345-350
10. Eigenbrot, C.; Ultsch, M.; Dubnovitsky, A.; Abrahmsén, L.; Härd, T. Structural Basis for High-Affinity HER2 Receptor Binding by an Engineered Protein Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 15039-15044
11. Shangguan, D.; Meng, L.; Cao, Z. C.; Xiao, Z.; Fang, X.; Li, Y.; Cardona, D.; Witek, R. P.; Liu, C.; Tan, W. Identification of Liver Cancer-Specific Aptamers Using Whole Live Cells Anal. Chem. 2008, 80, 721-728
12. Aina, O. H.; Liu, R.; Sutcliffe, J. L.; Marik, J.; Pan, C.-X.; Lam, K. S. From Combinatorial Chemistry to Cancer-Targeting Peptides Mol. Pharmaceutics 2007, 4, 631-651
13. Shukla, G. S.; Krag, D. N. Selection of Tumor-Targeting Agents on Freshly Excised Human Breast Tumors Using a Phage Display Library Oncol. Rep. 2005, 13 (4) 757-764
14. Shadidi, M, S. M. Selection of Peptides for Specific Delivery of Oligonucleotides into Cancer Cells Methods Mol. Biol. 2004, 252, 569-580
15. Shukla, G. S.; Krag, D. N. Novel β-Lactamase-Random Peptide Fusion Libraries for Phage Display Selection of Cancer Cell-Targeting Agents Suitable for Enzyme Prodrug Therapy J. Drug Targeting 2010, 18, 115-124
16. Zhang, J.; Spring, H.; Schwab, M. Neuroblastoma Tumor Cell-Binding Peptides Identified through Random Peptide Phage Display Cancer Lett. 2001, 171, 153-164
17. Askoxylakis, V.; Mier, W.; Zitzmann, S.; Ehemann, V.; Zhang, J.; Kramer, S.; Beck, C.; Schwab, M.; Eisenhut, M.; Haberkorn, U. Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells J. Nucl. Med. 2006, 47, 981-988
18. Askoxylakis, V.; Zitzmann, S.; Mier, W.; Graham, K.; Krämer, S.; von Wegner, F.; Fink, R. H. A.; Schwab, M.; Eisenhut, M.; Haberkorn, U. Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160 Clin. Cancer Res. 2005, 11, 6705-6712
19. Ahmed, S.; Mathews, A. S.; Byeon, N.; Lavasanifar, A.; Kaur, K. Peptide Arrays for Screening Cancer Specific Peptides Anal. Chem. 2010, 82, 7533-7541
20. Gorris, H. H.; Bade, S.; Röckendorf, N.; Albers, E.; Schmidt, M. A.; Fránek, M.; Frey, A. Rapid Profiling of Peptide Stability in Proteolytic Environments Anal. Chem. 2009, 81, 1580-1586
21. Adessi, C.; Soto, C. Converting a Peptide into a Drug: Strategies To Improve Stability and Bioavailability Curr. Med. Chem. 2002, 9 (9) 963-978
22. Gentilucci, L.; De Marco, R.; Cerisoli, L. Chemical Modifications Designed To Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization Curr. Pharm. Des. 2010, 16, 3185-3203
23. Horne, W. S.; Price, J. L.; Keck, J. L.; Gellman, S. H. Helix Bundle Quaternary Structure from α/β-Peptide Foldamers J. Am. Chem. Soc. 2007, 129, 4178-4180
24. Horne, W. S.; Johnson, L. M.; Ketas, T. J.; Klasse, P. J.; Lu, M.; Moore, J. P.; Gellman, S. H. Structural and Biological Mimicry of Protein Surface Recognition by α/β-Peptide Foldamers Proc. Natl. Acad. Sci. 2009, 106, 14751-14756
25. Ahmed, S.; Kaur, K. The Proteolytic Stability and Cytotoxicity Studies of l-Aspartic Acid and l-Diaminopropionic Acid Derived β-Peptides and a Mixed α/β-Peptide Chem. Biol. Drug Des. 2009, 73, 545-552
26. Frackenpohl, J.; Arvidsson, P. I.; Schreiber, J. V.; Seebach, D. The Outstanding Biological Stability of β- and γ-Peptides toward Proteolytic Enzymes: An in Vitro Investigation with Fifteen Peptidases ChemBioChem 2001, 2, 445-455
27. Hook, D. F.; Bindschädler, P.; Mahajan, Y. R.; Šebesta, R.; Kast, P.; Seebach, D. The Proteolytic Stability of "Designed" β-Peptides Containing α-Peptide-Bond Mimics and of Mixed α,β-Peptides: Application to the Construction of MHC-Binding Peptides Chem. Biodiversity 2005, 2, 591-632
28. Aguilar, M.-I.; Purcell, A. W.; Devi, R.; Lew, R.; Rossjohn, J.; Smith, A. I.; Perlmutter, P. [Small Beta]-Amino Acid-Containing Hybrid Peptides-New Opportunities in Peptidomimetics Org. Biomol. Chem. 2007, 5, 2884-2890
29. Ahmed, S.; Beleid, R.; Sprules, T.; Kaur, K. Solid-Phase Synthesis and CD Spectroscopic Investigations of Novel β-Peptides from l-Aspartic Acid and β-Amino-l-alanine Org. Lett. 2006, 9, 25-28
30. Kaiser, E, C. R.; Bossinger, C. D.; Cook, P. I. Color Test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides Anal. Biochem. 1970, 34, 595-598
31. Svenson, J.; Vergote, V.; Karstad, R.; Burvenich, C.; Svendsen, J. S.; De Spiegeleer, B. Metabolic Fate of Lactoferricin-Based Antimicrobial Peptides: Effect of Truncation and Incorporation of Amino Acid Analogs on the In Vitro Metabolic Stability J. Pharmacol. Exp. Ther. 2010, 332, 1032-1039
32. Güntert, P. Automated NMR Protein Structure Calculation with CYANA Methods Mol. Biol. 2004, 278, 353-378
33. van de Loosdrecht, A. A.; B. R., Ossenkoppele, G. J.; Broekhoven, M. G.; Langenhuijsen, M. M. A Tetrazolium-Based Colorimetric MTT Assay To Quantitate Human Monocyte Mediated Cytotoxicity against Leukemic Cells from Cell Lines and Patients with Acute Myeloid Leukemia J. Immunol. Methods 1994, 174, 311-320
34. Horne, W. S.; Boersma, M. D.; Windsor, M. A.; Gellman, S. H. Sequence-Based Design of α/β-Peptide Foldamers That Mimic BH3 Domains Angew. Chem., Int. Ed. 2008, 47, 2853-2856
35. Schröder-Borm, H.; Bakalova, R.; Andrä, J. The NK-Lysin Derived Peptide NK-2 Preferentially Kills Cancer Cells with Increased Surface Levels of Negatively Charged Phosphatidylserine FEBS Lett. 2005, 579, 6128-6134
36. Horne, W. S.; Gellman, S. H. Foldamers with Heterogeneous Backbones Acc. Chem. Res. 2008, 41, 1399-1408
37. Aravinda, S.; Datta, S.; Shamala, N.; Balaram, P. Hydrogen-Bond Lengths in Polypeptide Helices: No Evidence for Short Hydrogen Bonds Angew. Chem. 2004, 116, 6896-6899
38. Mahalakshmi, R.; Shanmugam, G.; Polavarapu, P. L.; Balaram, P. Circular Dichroism of Designed Peptide Helices and β-Hairpins: Analysis of Trp- and Tyr-Rich Peptides ChemBioChem 2005, 6, 2152-2158
39. Aravinda, S. S. N.; Desiraju, S; Balaram, P. A Right Handed Peptide Helix Containing a Central Double d -Amino Acid Segment Chem. Commun. 2002, 20, 2454-2455
40. Karle, I. L.; Gopi, H. N.; Balaram, P. Crystal Structure of a Hydrophobic 19-Residue Peptide Helix Containing Three Centrally Located d Amino Acids Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13946-13951
41. Sadowsky, J. D.; Fairlie, W. D.; Hadley, E. B.; Lee, H.-S.; Umezawa, N.; Nikolovska-Coleska, Z.; Wang, S.; Huang, D. C. S.; Tomita, Y.; Gellman, S. H. (α/β+α)-Peptide Antagonists of BH3 Domain/Bcl-xL Recognition: Toward General Strategies for Foldamer-Based Inhibition of Protein-Protein Interactions J. Am. Chem. Soc. 2006, 129, 139-154
42. Serova, M.; Galmarini, C. M.; Ghoul, A.; Benhadji, K.; Green, S. R.; Chiao, J.; Faivre, S.; Cvitkovic, E.; Le Tourneau, C.; Calvo, F.; Raymond, E. Antiproliferative Effects of Sapacitabine (CYC682), a Novel 2[Prime]- Deoxycytidine-Derivative, in Human Cancer Cells Br. J. Cancer 2007, 97, 628-636
43. Teixeira, R.; Barbosa, L.; Maltha, C.; Rocha, M.; Bezerra, D.; Costa-Lotuf, L.; Pessoa, C.; Moraes, M. Synthesis and Cytotoxic Activity of Some 3-Benzyl-5-Arylidenefuran-2(5 H)-ones Molecules 2007, 12, 1101-1116
44. Govindan, R. Cetuximab in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res. 2004, 10, 4241s-4244s
45. Sandler, A. B.; Johnson, D. H.; Herbst, R. S. Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer Clin. Cancer Res. 2004, 10, 4258s-4262s
46. Albanell, J, A. J.; Baselga, J; Codony-Servat, J; Molina, M. A.; Rojo, F Trastuzumab (Herpceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells Cancer Res. 2001, 61, 4744-4749
47. Shadidi, M.; Sioud, M. Selective Targeting of Cancer Cells Using Synthetic Peptides Drug Resist. Updates 2003, 6, 363-371
48. Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. β-Peptides: From Structure to Function Chem. Rev. 2001, 101, 3219-3232
49. Seebach, D.; Gardiner, J. β-Peptidic Peptidomimetics Acc. Chem. Res. 2008, 41, 1366-1375
50. Auzzas, L.; Zanardi, F.; Battistini, L.; Burreddu, P.; Carta, P.; Rassu, G.; Curti, C.; Casiraghi, G. Targeting v3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides Curr. Med. Chem. 2010, 17, 1255-1299
51. Wickström, M.; Larsson, R.; Nygren, P.; Gullbo, J. Aminopeptidase N (CD13) as a Target for Cancer Chemotherapy Cancer Sci. 2011, 102, 501-508
52. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs Science 2010, 328, 1031-1035
53. Shahin, M.; Ahmed, S.; Kaur, K.; Lavasanifar, A. Decoration of Polymeric Micelles with Cancer-Specific Peptide Ligands for Active Targeting of Paclitaxel Biomaterials 2011, 32, 5123-5133